JP6262731B2 - Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー - Google Patents
Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー Download PDFInfo
- Publication number
- JP6262731B2 JP6262731B2 JP2015525855A JP2015525855A JP6262731B2 JP 6262731 B2 JP6262731 B2 JP 6262731B2 JP 2015525855 A JP2015525855 A JP 2015525855A JP 2015525855 A JP2015525855 A JP 2015525855A JP 6262731 B2 JP6262731 B2 JP 6262731B2
- Authority
- JP
- Japan
- Prior art keywords
- genotype
- fgf
- treatment
- cartilage
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000003977 fibroblast growth factor 18 Human genes 0.000 title claims description 210
- 108090000370 fibroblast growth factor 18 Proteins 0.000 title claims description 210
- 150000001875 compounds Chemical class 0.000 title claims description 149
- 230000002068 genetic effect Effects 0.000 title description 27
- 239000003550 marker Substances 0.000 title description 25
- 230000004043 responsiveness Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 claims description 157
- 102220134620 rs9005 Human genes 0.000 claims description 100
- 238000000034 method Methods 0.000 claims description 81
- 208000015100 cartilage disease Diseases 0.000 claims description 69
- 206010061762 Chondropathy Diseases 0.000 claims description 43
- 150000007523 nucleic acids Chemical class 0.000 claims description 38
- 201000008482 osteoarthritis Diseases 0.000 claims description 35
- 230000035945 sensitivity Effects 0.000 claims description 30
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 206010007710 Cartilage injury Diseases 0.000 claims description 24
- 229950002135 sprifermin Drugs 0.000 claims description 24
- 238000011269 treatment regimen Methods 0.000 claims description 20
- 210000001188 articular cartilage Anatomy 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 14
- 238000001356 surgical procedure Methods 0.000 claims description 14
- 206010017076 Fracture Diseases 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 12
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000004614 Process Aid Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 description 114
- 239000000523 sample Substances 0.000 description 85
- 210000000845 cartilage Anatomy 0.000 description 73
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 69
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 69
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 69
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 69
- 108700028369 Alleles Proteins 0.000 description 66
- 101000690100 Homo sapiens U1 small nuclear ribonucleoprotein 70 kDa Proteins 0.000 description 59
- 101100029173 Phaeosphaeria nodorum (strain SN15 / ATCC MYA-4574 / FGSC 10173) SNP2 gene Proteins 0.000 description 59
- 101100094821 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SMX2 gene Proteins 0.000 description 59
- 102100024121 U1 small nuclear ribonucleoprotein 70 kDa Human genes 0.000 description 59
- 230000004044 response Effects 0.000 description 47
- 238000012360 testing method Methods 0.000 description 47
- 230000010398 acute inflammatory response Effects 0.000 description 42
- 206010020751 Hypersensitivity Diseases 0.000 description 37
- 108091034117 Oligonucleotide Proteins 0.000 description 36
- 239000002773 nucleotide Substances 0.000 description 34
- 125000003729 nucleotide group Chemical group 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 33
- 230000008859 change Effects 0.000 description 32
- 239000000902 placebo Substances 0.000 description 32
- 229940068196 placebo Drugs 0.000 description 31
- 239000013615 primer Substances 0.000 description 30
- 238000004458 analytical method Methods 0.000 description 29
- 238000003556 assay Methods 0.000 description 26
- 238000003205 genotyping method Methods 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 21
- 230000000875 corresponding effect Effects 0.000 description 20
- 102000054766 genetic haplotypes Human genes 0.000 description 16
- 102220134786 rs315952 Human genes 0.000 description 16
- 238000003908 quality control method Methods 0.000 description 15
- 230000006872 improvement Effects 0.000 description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 239000000090 biomarker Substances 0.000 description 12
- 239000012472 biological sample Substances 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 102000054765 polymorphisms of proteins Human genes 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000008439 repair process Effects 0.000 description 11
- 238000013517 stratification Methods 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000002987 primer (paints) Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 239000000975 dye Substances 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000002411 adverse Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000002595 magnetic resonance imaging Methods 0.000 description 7
- 238000011285 therapeutic regimen Methods 0.000 description 7
- 208000013201 Stress fracture Diseases 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 230000009610 hypersensitivity Effects 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000002751 oligonucleotide probe Substances 0.000 description 4
- 239000000092 prognostic biomarker Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- -1 Sprifermin (ie Chemical class 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000000968 fibrocartilage Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000002966 oligonucleotide array Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 108091033380 Coding strand Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 240000008168 Ficus benjamina Species 0.000 description 2
- 101001034207 Homo sapiens Mitochondrial folate transporter/carrier Proteins 0.000 description 2
- 101150074243 Il1rn gene Proteins 0.000 description 2
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 2
- 102100039811 Mitochondrial folate transporter/carrier Human genes 0.000 description 2
- 206010065159 Polychondritis Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000002436 femur neck Anatomy 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 230000003349 osteoarthritic effect Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 101150076141 rn gene Proteins 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000001148 Cartilage Fractures Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102100035308 Fibroblast growth factor 17 Human genes 0.000 description 1
- 108050002074 Fibroblast growth factor 17 Proteins 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
- 102100028121 Fos-related antigen 2 Human genes 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 208000007353 Hip Osteoarthritis Diseases 0.000 description 1
- 101001059934 Homo sapiens Fos-related antigen 2 Proteins 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LWQBAQJPCYBWJQ-BYPYZUCNSA-N N-carboxy-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(O)=O LWQBAQJPCYBWJQ-BYPYZUCNSA-N 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 206010073853 Osteochondral fracture Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101150062584 SNP1 gene Proteins 0.000 description 1
- 101150013578 SNP2 gene Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 208000026317 Tietze syndrome Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000003340 combinatorial analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 238000013079 data visualisation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000009169 relapsing polychondritis Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 102220133450 rs419598 Human genes 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12179391.3 | 2012-08-06 | ||
| EP12179391 | 2012-08-06 | ||
| US201261680480P | 2012-08-07 | 2012-08-07 | |
| US61/680,480 | 2012-08-07 | ||
| US201361778912P | 2013-03-13 | 2013-03-13 | |
| US61/778,912 | 2013-03-13 | ||
| PCT/EP2013/066421 WO2014023703A1 (fr) | 2012-08-06 | 2013-08-05 | Marqueurs génétiques pour la prédiction de la sensibilité à un composé fgf-18 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017236167A Division JP6496003B2 (ja) | 2012-08-06 | 2017-12-08 | Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015533078A JP2015533078A (ja) | 2015-11-19 |
| JP6262731B2 true JP6262731B2 (ja) | 2018-01-17 |
Family
ID=50067440
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525855A Active JP6262731B2 (ja) | 2012-08-06 | 2013-08-05 | Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー |
| JP2017236167A Active JP6496003B2 (ja) | 2012-08-06 | 2017-12-08 | Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017236167A Active JP6496003B2 (ja) | 2012-08-06 | 2017-12-08 | Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10221456B2 (fr) |
| EP (1) | EP2880179B1 (fr) |
| JP (2) | JP6262731B2 (fr) |
| CN (1) | CN104736723B (fr) |
| AU (1) | AU2013301606B2 (fr) |
| CA (1) | CA2881024C (fr) |
| ES (1) | ES2660818T3 (fr) |
| HK (1) | HK1207401A1 (fr) |
| IL (1) | IL237071B (fr) |
| WO (1) | WO2014023703A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018075019A (ja) * | 2012-08-06 | 2018-05-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105567847A (zh) * | 2016-02-22 | 2016-05-11 | 郑州大学 | 一种用MspI检测人胃癌易感基因IL-1RN多态性rs9005的方法 |
| CA3075713A1 (fr) | 2017-09-29 | 2019-04-04 | Merck Patent Gmbh | Biomarqueurs inflammatoires pour predire la reactivite a un compose fgf-18 |
| JP2020535436A (ja) * | 2017-09-29 | 2020-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｆｇｆ−１８化合物に対する反応性を予測する代謝バイオマーカー |
| KR102463200B1 (ko) * | 2017-12-08 | 2022-11-04 | 현대자동차 주식회사 | 차량용 도어 |
| CN108899086A (zh) * | 2018-06-11 | 2018-11-27 | 浙江大学 | 一种基于机器学习通过血液样本诊断骨关节炎亚型的系统 |
| SG11202102160VA (en) * | 2018-09-10 | 2021-04-29 | Merck Patent Gmbh | Markers useful in enrichment strategies for the treatment of osteoarthritis |
| WO2020161341A1 (fr) | 2019-02-08 | 2020-08-13 | Merck Patent Gmbh | Traitement de patients présentant un risque de progression rapide de l'ostéoarthrite |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989010414A1 (fr) | 1988-04-28 | 1989-11-02 | Robert Bruce Wallace | Polymorphismes (asp) a sequences amplifiees |
| IE66572B1 (en) | 1989-02-13 | 1996-01-24 | Geneco Pty Ltd | Detection of a nucleic acid sequence or a change therein |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US5302509A (en) | 1989-08-14 | 1994-04-12 | Beckman Instruments, Inc. | Method for sequencing polynucleotides |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| IL108159A (en) | 1993-12-23 | 1998-02-08 | Orgenics Ltd | Apparatus for separation, concentration and detection of target molecules in liquid sample |
| JP3175110B2 (ja) | 1994-02-07 | 2001-06-11 | オーキッド・バイオサイエンシーズ・インコーポレイテッド | リガーゼ／ポリメラーゼ媒体された単一ヌクレオチド多型のジェネティックビットアナリシスおよび遺伝子解析におけるその使用 |
| CA2240667A1 (fr) | 1995-12-18 | 1997-06-26 | Washington University | Procede d'analyse d'acide nucleique par transfert des energies de resonance par fluorescence |
| WO1998016644A1 (fr) | 1996-10-16 | 1998-04-23 | Zymogenetics, Inc. | Homologues de facteur de croissance fibroblastes (fgf) |
| AU2003279835B2 (en) | 2002-10-07 | 2009-09-10 | Zymogenetics, Inc. | Methods of administering FGF18 |
| DK1828239T3 (da) | 2004-12-10 | 2011-12-19 | Zymogenetics Inc | FGF18-produktion i prokaryote værter |
| AR062522A1 (es) * | 2006-08-25 | 2008-11-12 | Ares Trading Sa | Tratamiento de desordenes en cartilagos |
| CN101505787B (zh) * | 2006-08-25 | 2013-09-04 | 阿雷斯贸易股份有限公司 | 软骨障碍的治疗 |
| ES2708826T3 (es) * | 2008-05-02 | 2019-04-11 | Orig3N Inc | Detección de la predisposición genética a afecciones asociadas a la osteoartritis |
| US20120115137A1 (en) * | 2010-08-31 | 2012-05-10 | Kornman Kenneth S | Methods of Predicting Osteoarthritis |
| EP2880181B1 (fr) | 2012-08-06 | 2018-09-19 | Merck Patent GmbH | Biomarqueurs pour le pronostic des troubles du cartilage |
| CN104736723B (zh) * | 2012-08-06 | 2017-10-31 | 默克专利有限公司 | 用于预测对fgf‑18化合物的响应性的遗传标记 |
-
2013
- 2013-08-05 CN CN201380051772.1A patent/CN104736723B/zh active Active
- 2013-08-05 ES ES13745116.7T patent/ES2660818T3/es active Active
- 2013-08-05 CA CA2881024A patent/CA2881024C/fr active Active
- 2013-08-05 AU AU2013301606A patent/AU2013301606B2/en active Active
- 2013-08-05 EP EP13745116.7A patent/EP2880179B1/fr active Active
- 2013-08-05 JP JP2015525855A patent/JP6262731B2/ja active Active
- 2013-08-05 US US14/420,076 patent/US10221456B2/en active Active
- 2013-08-05 WO PCT/EP2013/066421 patent/WO2014023703A1/fr active Application Filing
-
2015
- 2015-02-03 IL IL237071A patent/IL237071B/en active IP Right Grant
- 2015-08-14 HK HK15107887.4A patent/HK1207401A1/xx unknown
-
2017
- 2017-12-08 JP JP2017236167A patent/JP6496003B2/ja active Active
-
2019
- 2019-02-13 US US16/274,361 patent/US20190161801A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018075019A (ja) * | 2012-08-06 | 2018-05-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015533078A (ja) | 2015-11-19 |
| HK1207401A1 (en) | 2016-01-29 |
| AU2013301606A1 (en) | 2015-03-05 |
| CA2881024C (fr) | 2021-06-15 |
| AU2013301606B2 (en) | 2018-08-02 |
| WO2014023703A1 (fr) | 2014-02-13 |
| US20150218637A1 (en) | 2015-08-06 |
| CN104736723A (zh) | 2015-06-24 |
| CA2881024A1 (fr) | 2014-02-13 |
| CN104736723B (zh) | 2017-10-31 |
| US20190161801A1 (en) | 2019-05-30 |
| US10221456B2 (en) | 2019-03-05 |
| JP2018075019A (ja) | 2018-05-17 |
| IL237071B (en) | 2018-12-31 |
| ES2660818T3 (es) | 2018-03-26 |
| EP2880179B1 (fr) | 2017-12-13 |
| EP2880179A1 (fr) | 2015-06-10 |
| JP6496003B2 (ja) | 2019-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6496003B2 (ja) | Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー | |
| US20090305900A1 (en) | Genemap of the human genes associated with longevity | |
| JP6272860B2 (ja) | 軟骨障害の予後バイオマーカー | |
| EP3507384B1 (fr) | Procédés et compositions pour la prédiction de l'activité d'enzastaurin | |
| MX2014004309A (es) | Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer. | |
| JP2007507460A (ja) | 炎症性疾患の治療効力と関連している遺伝子多型の使用 | |
| US20160076104A1 (en) | Methods and compositions for assessment of pulmonary function and disorders | |
| JP2004513609A (ja) | 薬理遺伝学試験の設計における非応答群の反復分析 | |
| US20060177860A1 (en) | Genetic markers in the HLA-DQBI gene associated with an adverse hematological response to drugs | |
| US20060183146A1 (en) | Genetic markers in the HLA-C gene associated with an adverse hematological response to drugs | |
| US20130281319A1 (en) | Methods and compositions for assessment of pulmonary function and disorders | |
| KR102650359B1 (ko) | 약물 과민반응 진단용 snp 및 이를 이용한 진단 방법 | |
| ES2702929T3 (es) | Biomarcadores para el pronóstico de trastornos del cartílago | |
| WO2007038155A2 (fr) | Methodes de diagnostic d'une maladie cardiovasculaire | |
| US20060178843A1 (en) | Genetic markers in the CSF2RB gene associated with an adverse hematological response to drugs | |
| WO2010033825A2 (fr) | Variants génétiques associés à des anévrismes de l'aorte abdominale | |
| EP3959333A1 (fr) | Utilisation de biomarqueurs pour une maladie discale dégénérative | |
| US20060147953A1 (en) | Methods of diagnosing cardiovascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160601 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170417 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170509 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170801 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171114 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171214 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6262731 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |